Akebia Therapeutics, Inc. (AKBA)
0.865
-0.01
(-0.69%)
USD |
NASDAQ |
Oct 02, 16:00
0.85
-0.02
(-1.73%)
After-Hours: 20:00
Akebia Therapeutics Enterprise Value : 288.61M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 288.61M |
| October 01, 2026 | 290.24M |
| September 30, 2026 | 303.56M |
| September 29, 2026 | 294.35M |
| September 28, 2026 | 296.25M |
| September 25, 2026 | 297.09M |
| September 24, 2026 | 303.29M |
| September 23, 2026 | 306.98M |
| September 22, 2026 | 319.86M |
| September 21, 2026 | 308.59M |
| September 18, 2026 | 302.39M |
| September 17, 2026 | 296.90M |
| September 16, 2026 | 302.96M |
| September 15, 2026 | 298.94M |
| September 14, 2026 | 315.22M |
| September 11, 2026 | 312.17M |
| September 10, 2026 | 310.76M |
| September 09, 2026 | 312.77M |
| September 08, 2026 | 333.45M |
| September 04, 2026 | 318.42M |
| September 03, 2026 | 320.76M |
| September 02, 2026 | 319.95M |
| September 01, 2026 | 310.27M |
| August 31, 2026 | 303.23M |
| August 28, 2026 | 292.31M |
| Date | Value |
|---|---|
| August 27, 2026 | 308.94M |
| August 26, 2026 | 299.89M |
| August 25, 2026 | 313.99M |
| August 24, 2026 | 298.29M |
| August 21, 2026 | 299.92M |
| August 20, 2026 | 303.40M |
| August 19, 2026 | 294.16M |
| August 18, 2026 | 285.03M |
| August 17, 2026 | 287.25M |
| August 14, 2026 | 290.73M |
| August 13, 2026 | 289.86M |
| August 12, 2026 | 296.28M |
| August 11, 2026 | 289.02M |
| August 10, 2026 | 282.91M |
| August 07, 2026 | 300.81M |
| August 06, 2026 | 312.91M |
| August 05, 2026 | 404.10M |
| August 04, 2026 | 412.26M |
| August 03, 2026 | 409.54M |
| July 31, 2026 | 412.26M |
| July 30, 2026 | 420.41M |
| July 29, 2026 | 395.95M |
| July 28, 2026 | 398.67M |
| July 27, 2026 | 401.39M |
| July 24, 2026 | 385.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Emergent BioSolutions, Inc. | 772.03M |
| Exelixis, Inc. | 13.86B |
| ADMA Biologics, Inc. | 2.258B |
| Arcutis Biotherapeutics, Inc. | 3.035B |
| Relay Therapeutics, Inc. | 3.263B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.908M |
| Revenue (Quarterly) | 49.13M |
| Total Expenses (Quarterly) | 58.04M |
| EPS Diluted (Quarterly) | -0.033 |
| Gross Profit Margin (Quarterly) | 77.59% |
| Profit Margin (Quarterly) | -18.13% |
| Earnings Yield | -12.83% |
| Normalized Earnings Yield | -13.69 |